Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

Updating Nektar in my Jubak Picks Portfolio ahead of a dangerous earnings season–and looking to add to positions on any plunge

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

What a difference a week makes for biotech stocks

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

Why Nektar is extremely oversold right now

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid

Nektar up 6.32% today on opioid data presentation

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200